Press Releases

Magellan Life Sciences® Pvt. Ltd. develops the first commercially viable production process for Brazzein

4th May 2017, Hyderabad, India

Magellan Life Sciences® has developed a proprietary (patent pending) production platform for Brazzein. The platform’s industry leading productivity level combined with simplified down-stream processing makes it the first commercially viable and scalable production process for Brazzein. Magellan’s co-founder, Dr. Abhiram Dukkipati adds “With increasing health awareness among consumers, food and beverage companies are aggressively exploring the next generation of natural sweeteners. Brazzein is that powerful natural sweetener which will have a disruptive impact on the sweetener market. Our platform overcomes production challenges that have so far hampered commercialization of Brazzein". With ongoing scale-up studies, the company has begun formulation trials with international food, dairy and beverage companies.

BRAZZEIN: Nature’s Ideal Zero Calorie Sweetener:

Brazzein is a natural sweet tasting molecule originally isolated from the exotic fruit “Oubli” found only in West Africa. It is 1000 times sweeter than sugar and:

• Has a taste profile that is closest to sugar

• No undesirable aftertaste

• A long history of safe consumption

• Heat and acid stable

• Has a low Glycemic Index

• Contributes negligible calories

All these features make it an ideal zero calorie natural sweetener. However, technical difficulties and prohibitive costs of extraction from limited natural sources or recombinant expression systems have prevented Brazzein from being used commercially.

Magellan Life Sciences® has developed a proprietary (patent pending) production platform for Brazzein. The platform’s industry leading productivity level combined with simplified down-stream processing makes it the first commercially viable and scalable production process for Brazzein. Magellan’s co-founder, Dr. Abhiram Dukkipati adds “With increasing health awareness among consumers, food and beverage companies are aggressively exploring the next generation of natural sweeteners. Brazzein is that powerful natural sweetener which will have a disruptive impact on the sweetener market. Our platform overcomes production challenges that have so far hampered commercialization of Brazzein”. With ongoing scale-up studies, the company has begun formulation trials with international food, dairy and beverage companies.

The market today for non-caloric high intensity sweeteners is estimated at six billion US Dollars. Due to the growing worldwide sugar associated epidemics, the market for these sweeteners is expected to double by 2020. Brazzein is ideally poised to capture a share of this global market and make a disruptive impact.

Magellan Life Sciences® Pvt. Ltd. is a privately held company founded in 2014 with its registered office in Hyderabad, India. Magellan’s mission is to develop a strong intellectual property portfolio of protein production technologies for a wide spectrum of end uses. It is the only company in Asia to offer the BacMam protein expression platform as a CRO service for outsourced projects.

 


 

BacMam Technology Pioneered By Dr. Abhiram Dukkipati Used For A Landmark Study By Stanford & MIT Researchers.

17th April 2015, Hyderabad, India

Dr. Abhiram Dukkipati, founder of Magellan Life Sciences® Pvt. Ltd., India, is part of a landmark study published in Science. He was part of a research team from Stanford University that for the first time, has successfully captured a 3- dimensional image of a highly complex viral molecule called US28 GPCR, from the human cytomegalovirus (HCMV). The study elucidates how virus use their own camouflaged molecules such as US28 to trick the body through "molecular mimicry" and divert any immune response directed towards them. The results from this study will serve as a foundation for future drug development efforts targeting the highly prevalent HCMV and related virus that affect majority of the worldwide population. The artificial synthesis of this complex molecule was mainly possible using Dr. Abhiram’s invention of the BacMam Platform for Structural Biology.

Relevance And Importance of US28GPCR:

The GPCR family is one of the most important family of proteins that determine how we taste, smell, see, hear or for that matter how our bodies react to outside stimuli and threats. GPCRs are responsible for the proper functioning of immune, sensory and biological systems. In spite of their importance, GPCRs are very technically challenging to synthesize in the lab. For this study, traditionally used platforms were not sophisticated enough to synthesize the quality and quantities needed of the highly complex US28 GPCR molecule. 

 

Impact On Future Discoveries:

In addition to this study, the BacMam platform has also recently facilitated the three dimensional structure determination efforts of many therapeutically important molecules involved in neurology, reproductive biology and immunology. This platform will undoubtedly lift many hurdles and pave way for many more such ground breaking studies that will have a big impact on understanding the basis for many life threatening diseases such as Cancer, HIV, CMV etc.

Dr Dukkipati adds, “It is really encouraging to know that the BacMam platform was a crucial technology in enabling this challenging study. BacMam is now a state-of-the-art platform that researchers are moving towards for synthesizing highly complex biological molecules for various kinds of studies. At  Magellan Life Sciences® Pvt., we are proud to be the first Asian company to offer this platform as an exclusive Knowledge Process Outsourcing service for our global biotech customers.”